New pill shows promise for Hard-to-Treat cancers in early trial
Disease control
Completed
This study tested a new drug called RP903 in 69 people with advanced solid tumors (like ovarian, breast, or cervical cancer) who had run out of standard options. The main goals were to check safety, find the best dose, and see if the drug shrinks tumors. It is an early-phase tria…
Phase: PHASE1 • Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC